Oxford Endovascular

Oxford Endovascular is a private, clinical-stage medical device company targeting the rapidly growing neurovascular intervention market, estimated at over $1 billion. The company is developing a patented, origami-engineered flow-diverter for the treatment of brain aneurysms, a condition affecting 1 in 50 people. With strong academic roots and over $10 million raised, including significant non-dilutive EU grant funding, the company is advancing toward first-in-human clinical studies. Its leadership combines deep clinical neuroradiology expertise with engineering innovation and seasoned medtech entrepreneurship.

Origami-engineered, minimally invasive implantable flow-diverter stents for treating intracranial aneurysms.

The market is dominated by large-cap medtech companies like Medtronic (Pipeline), Stryker (Neuroform Atlas, Surpass), and Johnson & Johnson (Cerus). Competition is fierce, but Oxford Endovascular's potential advantages in deliverability, conformability, and safety could differentiate it if proven clinically.